{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:38:56Z","timestamp":1768408736754,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1038\/s41409-021-01303-z","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T11:03:28Z","timestamp":1619607808000},"page":"2173-2182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of high-dose chemotherapy plus stem cell rescue on the survival of patients with neuroblastoma modified by MYCN gene gain\/amplification and remission status: a nationwide registration study in Japan"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7147-1019","authenticated-orcid":false,"given":"Yuya","family":"Saito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuyoshi","family":"Urashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Kiyotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Yuza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyoshi","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kikuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhki","family":"Koga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimikazu","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"1303_CR1","doi-asserted-by":"publisher","unstructured":"Yalcin B, Kremer LC, van Dalen EC. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev. 2015, Issue 8.\u00a0https:\/\/doi.org\/10.1002\/14651858.CD006301.pub3.","DOI":"10.1002\/14651858.CD006301.pub3"},{"key":"1303_CR2","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/JCO.2014.59.4648","volume":"33","author":"NR Pinto","year":"2015","unstructured":"Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33:3008\u201317.","journal-title":"J Clin Oncol"},{"key":"1303_CR3","doi-asserted-by":"publisher","first-page":"e27819","DOI":"10.1002\/pbc.27819","volume":"66","author":"K Campbell","year":"2019","unstructured":"Campbell K, Shyr D, Bagatell R, Fischer M, Nakagawara A, Nieto AC, et al. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: a report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2019;66:e27819.","journal-title":"Pediatr Blood Cancer"},{"key":"1303_CR4","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s10147-018-1281-8","volume":"23","author":"T Hishiki","year":"2018","unstructured":"Hishiki T, Matsumoto K, Ohira M, Kamijo T, Shichino H, Kuroda T, et al. Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG). Int J Clin Oncol. 2018;23:965\u201373.","journal-title":"Int J Clin Oncol"},{"key":"1303_CR5","doi-asserted-by":"publisher","first-page":"e27363","DOI":"10.1002\/pbc.27363","volume":"65","author":"DA Morgenstern","year":"2018","unstructured":"Morgenstern DA, Potschger U, Moreno L, Papadakis V, Owens C, Ash S, et al. Risk stratification of high-risk metastatic neuroblastoma: a report from the HR-NBL-1\/SIOPEN study. Pediatr Blood Cancer. 2018;65:e27363.","journal-title":"Pediatr Blood Cancer"},{"key":"1303_CR6","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1470-2045(17)30070-0","volume":"18","author":"R Ladenstein","year":"2017","unstructured":"Ladenstein R, Poetschger U, Pearson ADJ, Brock P, Luksch R, Castel V, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1\/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017;18:500\u201314.","journal-title":"Lancet Oncol"},{"key":"1303_CR7","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1002\/cncr.28687","volume":"120","author":"BH Kushner","year":"2014","unstructured":"Kushner BH, Modak S, Kramer K, LaQuaglia MP, Yataghene K, Basu EM, et al. Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era. Cancer. 2014;120:2050\u20139.","journal-title":"Cancer"},{"key":"1303_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/BF03006932","volume":"86","author":"Y Atsuta","year":"2007","unstructured":"Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol. 2007;86:269\u201374.","journal-title":"Int J Hematol"},{"key":"1303_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","volume":"103","author":"Y Atsuta","year":"2016","unstructured":"Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103:3\u201310.","journal-title":"Int J Hematol"},{"key":"1303_CR10","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.1200\/JCO.2005.02.014","volume":"23","author":"T Gotoh","year":"2005","unstructured":"Gotoh T, Hosoi H, Iehara T, Kuwahara Y, Osone S, Sugimoto T, et al. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction. J Clin Oncol. 2005;23:5205\u201310.","journal-title":"J Clin Oncol"},{"key":"1303_CR11","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","volume":"11","author":"GM Brodeur","year":"1993","unstructured":"Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466\u201377.","journal-title":"J Clin Oncol"},{"key":"1303_CR12","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","volume":"363","author":"AL Yu","year":"2010","unstructured":"Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl J Med. 2010;363:1324\u201334.","journal-title":"N. Engl J Med"},{"key":"1303_CR13","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S1470-2045(18)30578-3","volume":"19","author":"R Ladenstein","year":"2018","unstructured":"Ladenstein R, P\u00f6tschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, et al. Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1617\u201329.","journal-title":"Lancet Oncol"},{"key":"1303_CR14","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/JCO.2011.41.3807","volume":"30","author":"NK Cheung","year":"2012","unstructured":"Cheung NK, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K, et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol. 2012;30:3264\u201370.","journal-title":"J Clin Oncol"},{"key":"1303_CR15","doi-asserted-by":"publisher","first-page":"4155","DOI":"10.18632\/oncotarget.6393","volume":"7","author":"BH Kushner","year":"2016","unstructured":"Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Modak S, Kramer K, et al. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget. 2016;7:4155\u201366.","journal-title":"Oncotarget"},{"key":"1303_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.4143\/crt.2016.511","volume":"50","author":"L Amoroso","year":"2018","unstructured":"Amoroso L, Erminio G, Makin G, Pearson ADJ, Brock P, Valteau-Couanet D, et al. Topotecan-vincristine-doxorubicin in stage 4 high-risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC: A SIOPEN Study. Cancer Res Treat. 2018;50:148\u201355.","journal-title":"Cancer Res Treat"},{"key":"1303_CR17","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/cncr.10800","volume":"95","author":"BH Kushner","year":"2002","unstructured":"Kushner BH, Kramer K, Cheung NK. Chronic neuroblastoma. Cancer. 2002;95:1366\u201375.","journal-title":"Cancer"},{"key":"1303_CR18","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1200\/JCO.2010.34.3392","volume":"29","author":"WB London","year":"2011","unstructured":"London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011;29:3286\u201392.","journal-title":"J Clin Oncol"},{"key":"1303_CR19","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/bjc.2016.302","volume":"115","author":"NO Basta","year":"2016","unstructured":"Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J cancer. 2016;115:1048\u201357.","journal-title":"Br J cancer"},{"key":"1303_CR20","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1002\/cncr.30873","volume":"123","author":"K Campbell","year":"2017","unstructured":"Campbell K, Gastier-Foster JM, Mann M, Naranjo AH, Van Ryn C, Bagatell R, et al. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children\u2019s Oncology Group. Cancer. 2017;123:4224\u201335.","journal-title":"Cancer"},{"key":"1303_CR21","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1038\/sj.bjc.6605014","volume":"100","author":"PF Ambros","year":"2009","unstructured":"Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J cancer. 2009;100:1471\u201382.","journal-title":"Br J cancer"},{"key":"1303_CR22","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jama.2019.11642","volume":"322","author":"JR Park","year":"2019","unstructured":"Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA. 2019;322:746\u201355.","journal-title":"JAMA"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01303-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01303-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01303-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T23:25:10Z","timestamp":1630538710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01303-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1303"],"URL":"https:\/\/doi.org\/10.1038\/s41409-021-01303-z","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"assertion":[{"value":"15 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}